Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 9/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 15/20 | 0.55 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 4/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 7/20 | 0.44 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358701 | 1.00 | ITGA4 (0.55) | ITGA4ITGB1ITGB7ITGAVITGA5 | |
| SCHEMBL21376369 | 0.92 | ITGA4 (0.54) | ITGA4ITGB1ITGB7ALDH1A1 | |
| SCHEMBL21376376 | 0.91 | ITGA4 (0.51) | ITGA4ITGB1ITGAVITGA5ITGB8 | |
| SCHEMBL21376627 | 0.91 | ITGA4 (0.56) | ITGA4ITGB1ITGB7ITGAVITGA5 | |
| SCHEMBL21376642 | 0.90 | ITGA4 (0.50) | ITGA4ITGB1ITGB7ITGAVITGA5 | |
| SCHEMBL21376626 | 0.90 | ITGA4 (0.55) | ITGA4ITGB1ITGB7ITGAVITGA5 | |
| SCHEMBL21358813 | 0.89 | ITGB1 (0.55) | ITGA4ITGB1ITGB7ITGAVITGA5 | |
| SCHEMBL21358810 | 0.89 | ITGB1 (0.55) | ITGA4ITGB1ITGB7ITGAVITGA5 | |
| SCHEMBL21376629 | 0.88 | NPC1 (0.55) | ITGA4ITGB1ITGB7ITGAVITGA5 | |
| SCHEMBL21376368 | 0.85 | ITGA4 (0.49) | ITGA4ITGB1ITGB7ITGAVITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| EP-3765005-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | The Regents of the University of California (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | ITGA4 15/4885ITGB1 1/4885ITGB7 12/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | ITGA4 15/4885ITGB1 1/4885ITGB7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.